- Supported exchanges /
- F /
- 9VC.F
ATAI LIFE SCIENCES BV EO1 (9VC F) stock market data APIs
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
ATAI LIFE SCIENCES BV EO1 Financial Data Overview
| 0.9932 | |
| 0.9796 | |
| - | |
| 0.9932 | |
| 0.9796 | |
| 0.9434-2.475 | |
| 168 M | |
| 168 M | |
| 378 K | |
| 0.781 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ATAI LIFE SCIENCES BV EO1 Fundamental Data is available in our Financial Data APIs
- Net Revenue 378 K
- EBITDA -104 669 000
- Earnings Per Share -0.33
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ATAI LIFE SCIENCES BV EO1 Earnings via APIs
- Latest Release 2024-11-05
- EPS/Forecast NaN
Get ATAI LIFE SCIENCES BV EO1 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
